CTC
NBIX icon

Cetera Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Cetera Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$422K Buy
2,505
+75
+3% +$11.1K 0.21% 88
2026
Q1 		$320K Hold
2,430
– – 0.18% 108
2025
Q4 		$345K Hold
2,430
– – 0.18% 98
2025
Q3 		$341K Hold
2,430
– – 0.19% 94
2025
Q2 		$305K Buy
2,430
+240
+11% +$27.5K 0.18% 104
2025
Q1 		$242K Hold
2,190
– – 0.15% 138
2024
Q4 		$299K Hold
2,190
– – 0.19% 91
2024
Q3 		$252K Hold
2,190
– – 0.15% 133
2024
Q2 		$301K Hold
2,190
– – 0.19% 93
2024
Q1 		$302K Sell
2,190
-125
-5% -$17.1K 0.18% 98
2023
Q4 		$305K Buy
+2,315
New +$266K 0.19% 91

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cetera Trust Company's NBIX Position: Q2 2026 in Review

Cetera Trust Company increased its Neurocrine Biosciences (NBIX) stake by 3.1% in Q2 2026, buying an estimated $11.1K and bringing the position to 2,505 shares worth $422K. The position accounts for 0.21% of the portfolio, ranked #88.

Cetera Trust Company first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cetera Trust Company held 2,505 shares of Neurocrine Biosciences worth $422K as of Q2 2026.
  • Cetera Trust Company bought 75 Neurocrine Biosciences shares in Q2 2026, an estimated $11.1K.
  • Neurocrine Biosciences made up 0.21% of Cetera Trust Company's portfolio in Q2 2026, its #88 holding.
  • Cetera Trust Company first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cetera Trust Company's 13F filing for Q2 2026, filed 13 Aug 2026.